F. Barbanti

Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer.

L. Cacciari, F. Pannuti, D. Palenzona, 1979, European journal of cancer.

c-kit and SCF Expression in Normal and Tumor Breast Tissue

D. Amadori, D. Calistri, R. Silvestrini, 2004, Breast Cancer Research and Treatment.

[Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].

D. Amadori, A. Ravaioli, F. Barbanti, 1977, Minerva medica.

Prognostic factors in hereditary and sporadic breast cancers: analysis of an Italian series of 602 patients

F. Monti, S. Bartolini, L. Gianni, 1997 .